[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"generalised-lipodystrophy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:generalised-lipodystrophy":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100234123","measure-metreleptin-effectiveness-and-safety-registry-100234123",false,"NCT02325674","MEASuRE: Metreleptin Effectiveness And Safety Registry","MEASuRE","Inclusion Criteria:\n\n* Patients treated with metreleptin through commercial supply at the time or before enrolment into registry\n* Patients who provide a written consent\n* Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply\n\nExclusion Criteria:\n\n• Patients currently treated with an investigational agent as part of a clinical trial","ALL",{"count":18,"type":19},100,"ESTIMATED","10 Years","OBSERVATIONAL","The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.",[24,25],"Generalised Lipodystrophy","Partial Lipodystrophy",[27,28],"Lipodystrophy","Metreleptin Registry","RECRUITING","2026-01-16",{"date":32,"type":33},"2026-01-20","ACTUAL",{"date":35,"type":33},"2016-10-11",{"date":37,"type":19},"2031-10-31",{"name":39,"class":40},"Amryt Pharma","INDUSTRY",28]